NCT00644800View on ClinicalTrials.gov

A Study of the Efficacy and Safety of Intramuscular Ziprasidone Followed by Oral Ziprasidone for the Treatment of Psychosis

PHASE4CompletedINTERVENTIONAL
Enrollment

89

Participants

Timeline

Start Date

July 31, 2003

Study Completion Date

May 31, 2004

Conditions
SchizophreniaManiaDelusional DisorderAcute Exacerbation of Psychosis
Interventions
DRUG

Ziprasidone

Intramuscular ziprasidone 10 or 20 mg at the investigator's discretion for 1 to 3 days followed by oral ziprasidone capsules 40 to 80 mg twice daily at the investigator's discretion to complete 7 days of treatment

Trial Locations (8)

60175-270

Pfizer Investigational Site, Fortaleza

41180-000

Pfizer Investigational Site, Salvador

30150-270

Pfizer Investigational Site, Belo Horizonte

Unknown

Pfizer Investigational Site, Curitiba

Pfizer Investigational Site, Rio de Janeiro

Pfizer Investigational Site, São Gonçalo

Pfizer Investigational Site, São Paulo

40340-720

Pfizer Investigational Site, Jardim Santa Monica SN

All Listed Sponsors
lead

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

INDUSTRY

NCT00644800 - A Study of the Efficacy and Safety of Intramuscular Ziprasidone Followed by Oral Ziprasidone for the Treatment of Psychosis | Biotech Hunter | Biotech Hunter